PuriCore's Vashe shown to be effective

UK-headquartered PuriCore has announced new clinical results from successful case studies showing the safety and efficacy of its US Food and Drug Administration-cleared Vashe Wound Therapy Solution in a variety of applications. To date, nine physicians at 13 US clinical sites have used Vashe successfully to treat more than 2,000 patients with a diverse range of chronic and acute wounds with no report of adverse effects. The Vashe System produces hypochlorous acid at near-neutral pH, the same antimicrobial solution produced by the human body to fight infection.

The clinicians reported positive results and efficacy of Vashe for the treatment of a variety of challenging wounds including chronic venous ulcers; non-healing surgical wounds; and necrotizing fasciitis, a rare, life-threatening bacterial infection of the skin, subcutaneous tissue and superficial facia with a mortality rate of 20 to 60%. Five patients suffering from necrotizing fasciitis were successfully treated with the Vashe Solution.